Compare IDYA & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | TWST |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2019 | 2018 |
| Metric | IDYA | TWST |
|---|---|---|
| Price | $32.46 | $56.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $52.86 | $46.88 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.90 | ★ 63.89 |
| EPS | N/A | ★ N/A |
| Revenue | $218,710,000.00 | ★ $376,572,000.00 |
| Revenue This Year | N/A | $18.91 |
| Revenue Next Year | $199.11 | $15.07 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3024.43 | 20.32 |
| 52 Week Low | $16.81 | $23.30 |
| 52 Week High | $39.28 | $59.90 |
| Indicator | IDYA | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 64.73 |
| Support Level | $29.29 | $41.85 |
| Resistance Level | $34.76 | $57.88 |
| Average True Range (ATR) | 2.09 | 3.25 |
| MACD | 0.12 | 1.00 |
| Stochastic Oscillator | 30.74 | 82.32 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.